While the potent inhibitors of GAT1 are used to treat epileptic seizures, the in vivo studies demonstrating the ability of BGT-1 to impact the severity of epileptic seizures, raised a possibility of functional similarities between GAT1 and BGT-1. The gene discussed is SLC6A12; the disease is Seizure.